BFM
GRCL

Boothbay Fund Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Boothbay Fund Management’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,782
Closed -$163K – 2313
2021
Q3 		$163K Sell
11,782
-2,261
-16% -$26.7K ﹤0.01% 1644
2021
Q2 		$183K Buy
+14,043
New +$188K 0.01% 1552

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boothbay Fund Management's GRCL Position: Q4 2021 in Review

Boothbay Fund Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q4 2021, closing a stake of 11,782 shares — an estimated $163K sold.

Boothbay Fund Management first reported a position in GRCL in Q2 2021 and held it in 2 quarters. The position peaked at $183K in Q2 2021. 35 funds tracked by Wall St. Rank hold GRCL as of Q4 2021.

  • Boothbay Fund Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q4 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 11,782 Gracell Biotechnologies Inc. American Depositary Shares shares in Q4 2021, an estimated $163K.
  • Boothbay Fund Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2021 and held it in 2 quarters.
  • Boothbay Fund Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $183K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q4 2021.

Based on Boothbay Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.